Evidence map›Paper›PMID 40580483›Full record

ReviewGut microbes2025

Dysfunctional circadian-driven dynamics in gut microbiota and tumor microenvironment.

Taoxing Peng, Yiqi Wan, Yuxuan Sun, Yuexiang Ren, Fuli Shi, Yangfeng Lv, Xiangqiong Wen, Qiongfeng Chen, Xianhe Yang, Shan Xu and 1 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Gut microbes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Taoxing PengThe MOE Basic Research and Innovation Center for the Targeted Therapeutics of Solid Tumors, Department of Pathology and Institute of Molecular Pathology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.ORCID 0009-0003-5577-9103
Yiqi WanThe MOE Basic Research and Innovation Center for the Targeted Therapeutics of Solid Tumors, Department of Pathology and Institute of Molecular Pathology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
Yuxuan SunThe MOE Basic Research and Innovation Center for the Targeted Therapeutics of Solid Tumors, Department of Pathology and Institute of Molecular Pathology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
Yuexiang RenThe MOE Basic Research and Innovation Center for the Targeted Therapeutics of Solid Tumors, Department of Pathology and Institute of Molecular Pathology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
Fuli ShiThe MOE Basic Research and Innovation Center for the Targeted Therapeutics of Solid Tumors, Department of Pathology and Institute of Molecular Pathology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
Yangfeng LvSchool of Basic Medical Sciences, Nanchang University, Nanchang, China.
Xiangqiong WenDepartment of General Surgery, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
Qiongfeng ChenThe MOE Basic Research and Innovation Center for the Targeted Therapeutics of Solid Tumors, Department of Pathology and Institute of Molecular Pathology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
Xianhe YangThe MOE Basic Research and Innovation Center for the Targeted Therapeutics of Solid Tumors, Department of Pathology and Institute of Molecular Pathology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
Shan XuThe MOE Basic Research and Innovation Center for the Targeted Therapeutics of Solid Tumors, Department of Pathology and Institute of Molecular Pathology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
Jianming LiThe MOE Basic Research and Innovation Center for the Targeted Therapeutics of Solid Tumors, Department of Pathology and Institute of Molecular Pathology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Circadian rhythms govern physiological activities through the precise modulation of gene expression and biochemical functions. Dysfunction of circadian rhythms is associated with an increased risk of tumor formation, growth, and metastasis, as well as alterations in the gut microbiota (GM) and the tumor microenvironment (TME). Indeed, the intricate regulatory interactions between the circadian system, GM, and TME present a promising area for further exploration. This review, centered on the circadian system, focuses on the dynamics in the GM and the TME driven by circadian dysfunction. Additionally, it places particular emphasis on the interplay between circadian rhythms and GM. The review further explores how this interplay can be therapeutically leveraged to normalize the TME and enhance clinical outcomes. For the first time, the rhythms-microbiota-microenvironment axis is proposed, linking the circadian system, GM, and TME. Circadian dysfunction significantly impacts this axis, leading to disruptions in both the GM and TME. The review also provides the latest insights and innovative therapies from the perspective of the interplay between circadian rhythms and GM.

Indexed as

Circadian RhythmGastrointestinal MicrobiomeNeoplasmsTumor MicroenvironmentAnimalsHumansCircadian rhythmsgut microbiotametabolitesrhythms-microbiota-microenvironment axistumor microenvironment

Identifiers

PMID40580483
PMCPMC12218547

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.